Krystal Biotech Inc (NASDAQ:KRYS) reported upbeat earnings for the first quarter on Monday.

The company posted quarterly earnings of $1.83 per share which beat the analyst consensus estimate of $1.39 per share. The company reported quarterly sales of $116.357 million which beat the analyst consensus estimate of $112.132 million.

“Following a successful 2025, we are entering 2026 with strong momentum, including two potential registrational study readouts and continued global expansion for VYJUVEK,” said Krish S. Krishnan, Chairman and Chief Executive Officer of Krystal Biotech. “With three pipeline products receiving platform designation, each development milestone strengthens the regulatory dataset, which could accelerate future programs and potentially reduce development risk. This compounding advantage underscores the value of the platform model we have been building since day one.”

Krystal Biotech shares fell 1% to trade at $284.01 on Tuesday.

These analysts made changes to their price targets on Krystal Biotech following earnings announcement.

  • Evercore ISI Group analyst Gavin Clark-Gartner maintained Krystal Biotech with an Outperform rating and raised the price target from $295 to $300.
  • Citigroup analyst Yigal Nochomovitz maintained the stock with a Buy and raised the price target from $371 to $378.

Considering buying KRYS stock? Here’s what analysts think:

Photo via Shutterstock